Initially discovered as abundant components of eukaryotic cell membranes, sphingolipids are now recognized as important bioactive signaling molecules that modulate a variety of cellular functions, including those relevant to cancer and immunologic, inflammatory, and cardiovascular disorders. In this review, we discuss recent advances in our understanding of the role of sphingosine-1-phosphate (S1P) receptors in the regulation of vascular function, and focus on how de novo biosynthesized sphingolipids play a role in blood pressure homeostasis. The therapeutic potential of new drugs that target S1P signaling is also discussed.
- Received March 2, 2016.
- Accepted June 13, 2016.
This work was supported by the National Institutes of Health [Grant R01HL126913] and the Harold S. Geneen Charitable Trust Award for Coronary Heart Disease Research (to A.D.L.).
- Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics